Royalty Pharma plc
RPRX
$32.87
-$0.48-1.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.09B | 858.98M | 1.15B | 673.24M | 798.86M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 20.49M | 19.56M | 19.10M | 18.76M | 19.52M |
| Total Other Non-Cash Items | -1.50B | -1.15B | -1.37B | -923.82M | -1.01B |
| Change in Net Operating Assets | 3.09B | 3.04B | 3.00B | 2.90B | 2.81B |
| Cash from Operations | 2.70B | 2.77B | 2.80B | 2.67B | 2.62B |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.09B | -2.68B | -3.17B | -2.43B | -1.60B |
| Cash from Investing | -2.09B | -2.68B | -3.17B | -2.43B | -1.60B |
| Total Debt Issued | 1.47B | 1.47B | 1.82B | 1.82B | 350.00M |
| Total Debt Repaid | -- | -- | -350.00M | -1.35B | -1.35B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -938.43M | -229.65M | -207.24M | -250.32M | -304.76M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -378.02M | -376.47M | -372.15M | -367.84M | -363.50M |
| Other Financing Activities | -522.94M | -503.97M | -504.63M | -499.85M | -482.12M |
| Cash from Financing | -368.16M | 361.15M | 387.21M | -646.77M | -2.15B |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 244.72M | 452.02M | 13.60M | -408.43M | -1.13B |